Sign in Subscribe
Immunotherapy

Immunotherapy in EGFR-Mutant NSCLC After TKI Resistance: A Multicenter Analysis

Strategic Insights

— 2 min read

Investigators from the First Affiliated Hospital and other Chinese institutions published a new report on the effectiveness of immunotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have developed resistance to tyrosine kinase inhibitors (TKIs). The study analyzed comprehensive treatment data from 312 patients with EGFR-mutant NSCLC, focusing on the predictive biomarkers guiding optimal patient selection for immunotherapy. The research found that resistance subtype and mutation profile may aid immunotherapy selection, with patients with primary resistance and L858R mutations deriving clinically meaningful benefit from immune checkpoint inhibitors (ICIs), while those with acquired resistance showed limited efficacy.

Key Takeaways:

  • The study analyzed 312 patients with EGFR-mutant NSCLC from five Chinese institutions, with comprehensive treatment data collected on EGFR-TKIs, platinum-based chemotherapy, anti-angiogenic agents, and immune checkpoint inhibitors (ICIs).
  • Cox proportional hazards regression identified progression-free survival (PFS)-associated variables, enabling resistance subtyping, and comparative effectiveness analyses across therapeutic modalities were performed.
  • Two independent predictors of immunotherapy PFS were identified: EGFR mutation subtypes (exon21 L858R vs. exon19del; HR 0.84, 95% CI [0.70-0.99], P = 0.042) and TKI resistance classification (acquired vs. primary: HR 2.28, 95% CI [1.52-3.43], P = 0.001).
  • Patients with primary TKI resistance showed improved outcomes with ICIs, particularly in L858R-mutant subgroups, with a median PFS of 8.5 vs. 4.0 months (HR 0.46, 95 % CI [0.29-0.76], P = 0.002).
  • Acquired resistance cohorts, especially those with exon19del mutations, derived limited clinical benefit from ICIs (HR 1.09, 95 % CI [0.84-1.42]; P = 0.510).
  • The study suggests that resistance subtype and mutation profile may aid immunotherapy selection in EGFR-mutant NSCLC, requiring validation through prospective studies.

Statistics:

  • 1,396 EGFR-mutant NSCLC patients were analyzed from five Chinese institutions.
  • 312 patients met the inclusion criteria.
  • The study collected comprehensive treatment data on EGFR-TKIs, platinum-based chemotherapy, anti-angiogenic agents, and ICIs.
  • Median PFS was 8.5 months in patients with primary TKI resistance and L858R mutations.
  • Median PFS was 4.0 months in patients with acquired TKI resistance and exon19del mutations.

Sources:

  • NewsRx. Research Data from First Affiliated Hospital Update Understanding of Immunotherapy (Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns). Immunotherapy Weekly. September 3, 2025; p 1958.
  • Dai, X., et al. (2025). Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns. Lung Cancer, 207, 108715.

Read more